Last reviewed · How we verify
Decadron Phosphate, Injectable
Dexamethasone phosphate is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm.
Dexamethasone phosphate is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm. Used for Inflammatory and allergic disorders, Rheumatoid arthritis and other autoimmune conditions, Cerebral edema.
At a glance
| Generic name | Decadron Phosphate, Injectable |
|---|---|
| Sponsor | Hospital for Special Surgery, New York |
| Drug class | Glucocorticoid (corticosteroid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Oncology (supportive care) |
| Phase | FDA-approved |
Mechanism of action
Dexamethasone phosphate enters cells and binds to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene transcription. This leads to decreased production of pro-inflammatory cytokines, reduced immune cell activation and proliferation, and suppression of inflammatory mediators. The injectable phosphate ester formulation allows for rapid systemic delivery and is commonly used for acute inflammatory and immunological conditions.
Approved indications
- Inflammatory and allergic disorders
- Rheumatoid arthritis and other autoimmune conditions
- Cerebral edema
- Acute leukemia (supportive care)
- Severe infections with systemic inflammation
Common side effects
- Hyperglycemia
- Insomnia
- Mood changes (euphoria, irritability)
- Increased infection risk
- Hypertension
- Osteoporosis (with chronic use)
- Adrenal suppression
Key clinical trials
- Dose Dependent Steroid Injections (PHASE4)
- A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma (PHASE1, PHASE2)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients (PHASE2)
- Post-operative Methylprednisolone Taper Course for Orthopedic Surgery (PHASE4)
- Venetoclax Basket Trial for High Risk Hematologic Malignancies (PHASE1)
- Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma (PHASE2)
- Dexamethasone for Ureteral STent Symptoms (DUSTS) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |